Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Radiology

The Diagnostic Journey: Imaging, Biopsy, and Biomarkers

At a Glance

Kaposiform lymphangiomatosis is diagnosed by combining CT or MRI findings with clinical and laboratory information, pathology when safe, and sometimes NRAS Q61R testing of blood or pleural fluid. A negative biopsy or liquid-biopsy result alone does not rule it out.

Confirming a diagnosis of Kaposiform lymphangiomatosis (KLA) requires a multidisciplinary approach. Because KLA can look similar to other conditions under a microscope, doctors must integrate what they see on high-tech scans, laboratory findings, and the genetic “fingerprint” of the disease [1][2].

Advanced Imaging: Mapping the Disease

Imaging is often the first step in identifying KLA. Doctors use different types of scans to see how the disease is affecting the body’s internal structures:

  • CT Scans: These are often used for a rapid, detailed look at the chest. In KLA, CT scans frequently show “infiltrative” soft tissue in the mediastinum (the center of the chest) and fluid around the lungs or heart [1].
  • MRI: Conventional MRI is excellent for mapping out the full extent of the disease in the bones, abdomen, and muscles without using radiation [1].
  • Dynamic Contrast-Enhanced MR Lymphangiography (DCMRL): This is a specialized scan where a contrast agent is injected into the lymph nodes. It allows doctors to watch how lymph fluid moves in real-time, which helps them identify exactly where the vessels are leaking or blocked [3][4].

Pathology and the “Spindle Cell”

If a biopsy is performed, a pathologist looks at a tissue sample under a microscope. In KLA, the hallmark finding is the presence of malformed, dilated lymphatic channels and sparse clusters of spindle cells—cells that are long and thin rather than round [5][6].

To support that these are lymphatic cells, pathologists use “stains” to look for specific markers:

  • D2-40 (Podoplanin) and PROX1: These are proteins often found in lymphatic cells [5][6].
  • CD31: A marker that identifies cells lining blood and lymph vessels [5].

The Challenge of Biopsy: Biopsies in KLA carry significant risks. Because KLA affects blood clotting and the abnormal vessels can bleed easily, a biopsy can sometimes cause a serious hemorrhage [7]. Additionally, because the spindle cells are often scattered (sampling error), a small biopsy might miss them entirely [8][9]. Diagnosis ultimately relies on the whole clinical and imaging picture; a missing stain or negative biopsy does not automatically invalidate the diagnosis.

Genetic Testing and Liquid Biopsy

Because of the risks of traditional biopsy, many centers are testing cell-free DNA (cfDNA), an emerging tool sometimes called a “liquid biopsy” [10]. When cells die, they release tiny fragments of DNA into the blood or into the fluid collected in the chest (pleural effusion) [10][11].

Specialized labs can test this fluid for the NRAS Q61R mutation [9]. Finding this mutation can support the diagnosis even if a tissue biopsy is too dangerous. However, detection depends on the sample type, disease burden, and assay sensitivity. A negative result does not rule out KLA, and the results must always be interpreted alongside clinical findings and imaging.

Emerging Biomarkers: Ang-2

A protein called Angiopoietin-2 (Ang-2) is being studied as a potential investigational biomarker for KLA. In specific research cohorts, levels of Ang-2 were often much higher (sometimes 10 times higher) in KLA patients compared to those with other lymphatic conditions [12][6].

  • At Diagnosis: An elevated Ang-2 level may help support the diagnosis of KLA [12].
  • During Treatment: As medications begin to work, Ang-2 levels typically dropped in the studied cohorts [12][13]. Doctors in specialized centers sometimes use serial Ang-2 tests to monitor how well the treatment is controlling the disease [14].

However, Ang-2 is not a universally available or universally validated routine diagnostic test. An elevated or falling value cannot by itself diagnose KLA or prove treatment success. If this test is unavailable, clinicians rely firmly on your clinical status, standard blood tests (like platelets and fibrinogen), and imaging.

Questions for the Pathology Team

If you have a pathology report, these are useful questions to ask your specialist to understand the context of the findings:

  • [ ] Morphology: Does it mention dilated lymphatic channels and spindle cells? [5]
  • [ ] Immunohistochemistry: Were stains for D2-40, PROX1, and CD31 supportive of the diagnosis? [5][6]
  • [ ] Architecture: Is there an absence of the thick “hyaline fibrosis” or dense nodules typically seen in KHE? [15]
  • [ ] Molecular Testing: Was the tissue or fluid tested for the NRAS Q61R mutation, and what are the limitations of that test? [9]

Common questions in this guide

Which scans are used to diagnose kaposiform lymphangiomatosis?
CT can provide a rapid, detailed view of the chest, while MRI can map disease in the bones, abdomen, and muscles without radiation. Dynamic contrast-enhanced MR lymphangiography can show lymph-fluid movement and help locate leaking or blocked vessels.
What might a biopsy show in KLA?
A biopsy may show abnormal, widened lymphatic channels and scattered spindle cells, which are long, thin cells. Stains such as D2-40, PROX1, and CD31 can support that the cells are related to lymphatic or vessel linings, but the findings must be interpreted with imaging and clinical information.
Why can a biopsy be risky in kaposiform lymphangiomatosis?
KLA can affect blood clotting, and abnormal vessels may bleed heavily during the procedure. Because spindle cells can be scattered, a small sample may miss them, so a negative biopsy does not automatically rule out KLA.
Can a liquid biopsy detect KLA?
A liquid biopsy analyzes cell-free DNA in blood or pleural fluid for the NRAS Q61R mutation. Finding the mutation can support a KLA diagnosis, but a negative result does not rule it out because detection depends on the sample, disease burden, and test sensitivity.
What does Ang-2 testing tell you about KLA?
Angiopoietin-2, or Ang-2, is an investigational biomarker that has been higher in some KLA research cohorts and may fall as treatment works. It is not a universally available or validated routine test, so an Ang-2 result cannot diagnose KLA or prove treatment success by itself.

Get notified when new evidence is published on Kaposiform lymphangiomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Imaging features of kaposiform lymphangiomatosis.

    Goyal P, Alomari AI, Kozakewich HP, et al.

    Pediatric radiology 2016; (46(9)):1282-90 doi:10.1007/s00247-016-3611-1.

    PMID: 27053281
  2. 2

    Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus.

    Iacobas I, Adams DM, Pimpalwar S, et al.

    Pediatric blood & cancer 2020; (67(1)):e28036 doi:10.1002/pbc.28036.

    PMID: 31617676
  3. 3

    Complex lymphatic anomalies.

    Alkhulaifat D, Ramirez-Suarez KI, Otero HJ, et al.

    Pediatric radiology 2025; (55(11)):2348-2355 doi:10.1007/s00247-025-06167-9.

    PMID: 39853393
  4. 4

    Imaging of complex lymphatic anomalies in children.

    Klein WM, Biko DM, Gerwins P, Petit P

    Pediatric radiology 2026; doi:10.1007/s00247-026-06608-z.

    PMID: 42024244
  5. 5

    Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients.

    Perez-Atayde AR, Debelenko L, Al-Ibraheemi A, et al.

    The American journal of surgical pathology 2022; (46(7)):963-976 doi:10.1097/PAS.0000000000001898.

    PMID: 35385405
  6. 6

    Potential biomarkers of kaposiform lymphangiomatosis.

    Ozeki M, Nozawa A, Kawamoto N, et al.

    Pediatric blood & cancer 2019; (66(9)):e27878 doi:10.1002/pbc.27878.

    PMID: 31207041
  7. 7

    Kaposiform lymphangiomatosis presenting with a Group A Streptococcus pericardial effusion.

    Koerner T, Patel MD, Pai V, Indramohan G

    BMJ case reports 2022; (15(3)) doi:10.1136/bcr-2021-246250.

    PMID: 35232734
  8. 8

    How we use angiopoietin-2 in the diagnosis and management of vascular anomalies.

    Engel ER, Le Cras TD, Ricci KW

    Pediatric blood & cancer 2024; (71(5)):e30921 doi:10.1002/pbc.30921.

    PMID: 38439088
  9. 9

    A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.

    Barclay SF, Inman KW, Luks VL, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(7)):1517-1524 doi:10.1038/s41436-018-0390-0.

    PMID: 30542204
  10. 10

    Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.

    Ozeki M, Aoki Y, Nozawa A, et al.

    Orphanet journal of rare diseases 2019; (14(1)):215 doi:10.1186/s13023-019-1191-5.

    PMID: 31511039
  11. 11

    Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.

    Brown G, McNab S, Keogh S, et al.

    Case reports in pediatrics 2026; (2026()):7037459 doi:10.1155/crpe/7037459.

    PMID: 42639465
  12. 12

    Angiopoietins as serum biomarkers for lymphatic anomalies.

    Le Cras TD, Mobberley-Schuman PS, Broering M, et al.

    Angiogenesis 2017; (20(1)):163-173 doi:10.1007/s10456-016-9537-2.

    PMID: 27990590
  13. 13

    Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin-2 levels.

    Crane J, Manfredo J, Boscolo E, et al.

    Pediatric blood & cancer 2020; (67(9)):e28529 doi:10.1002/pbc.28529.

    PMID: 32634277
  14. 14

    Trametinib normalizes angiopoietin-2 levels and successfully treats kaposiform lymphangiomatosis.

    McDaniel CG, Merkle S, Lacuna S, et al.

    Journal of vascular anomalies 2025; (6(4)) doi:10.1097/jova.0000000000000124.

    PMID: 41788185
  15. 15

    Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.

    Ji Y, Chen S, Peng S, et al.

    Orphanet journal of rare diseases 2019; (14(1)):165 doi:10.1186/s13023-019-1147-9.

    PMID: 31277673

This page is for informational purposes only and does not constitute medical advice. A specialist should interpret your imaging, biopsy, blood tests, and biomarker results in the context of your care.